<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nDiabetes continues to be a major public health concern in India. According to the World Health Organization (WHO), it is estimated that around 77 million adults are presently living with type 2 diabetes and nearly 25 million are classified as prediabetic. The situation is further alarming, with over half of these individuals remaining unaware of their condition. This may increase the risk of preventable complications such as diabetic foot ulcers, vision loss (from diabetic retinopathy), chronic kidney disease, heart attacks, and even strokes ^{1<\/sup><\/a>. Fortunately, as the burden of diabetes and its related complications grows, newer therapeutic classes have emerged to help people manage this condition.\u00a0\u00a0<\/p>\n\n\n\n}
Glucagon-like peptide-1 receptor agonists represent one such important advancement that offers multiple benefits in the management of type 2 diabetes. Meta-analysis and observational studies have shown that Indian patients respond to GLP-1 RAs similarly to populations globally ^{2<\/sup><\/a>^,<\/sup>}^{3<\/sup><\/a>. This makes them a valuable option within modern diabetes care in India.\u00a0<\/p>\n\n\n\n}
Therefore, through this article, we aim to provide informational awareness about GLP-1 drugs and their role in managing type 2 diabetes.\u00a0<\/p>\n\n\n\n
<\/span>What is GLP-1?<\/strong><\/span><\/h2>\n\n\n\n
GLP-1 full form is glucagon-like peptide-1, and it refers to a natural gut hormone that helps regulate blood sugar, digestion, and even appetite.\u00a0<\/p>\n\n\n\n
The regulation of blood glucose levels (sugar levels) in people with type 2 diabetes is often disrupted. In such cases, GLP-1 hormone can help contribute to glucose control by stimulating glucose-dependent insulin release, reducing glucagon secretion, slowing gastric emptying, and eventually enhancing satiety.\u00a0\u00a0<\/p>\n\n\n\n
Since GLP-1 acts on multiple pathways that are not fully addressed by other therapies, GLP-1 receptor agonists (drugs that mimic GLP-1 to improve insulin response and reduce glucose levels) have become the foundation for medications used in modern diabetes management ^{3<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
<\/span>What Are GLP-1 RAs?<\/strong><\/span><\/h2>\n\n\n\nGlucagon-like peptide-1 receptor agonists or GLP-1 RA definition includes a class of medications that act in a similar manner to the GLP-1 hormone. These medications are used to manage type 2 diabetes mellitus and, in some cases, obesity ^{3<\/sup><\/a>^,<\/sup>}^{4<\/sup><\/a>.\u00a0\u00a0<\/p>\n\n\n\n}
Regulatory authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the Central Drugs Standard Control Organisation (CDSCO) in India, have approved GLP-1 RAs <\/strong>based on their safety and efficacy^{3<\/sup><\/a>^,<\/sup>}^{6<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
Their primary indication is the management of type 2 diabetes, where they are used alongside diet and exercise to improve glycaemic control by enhancing insulin secretion, suppressing glucagon, and supporting healthier glucose regulation ^{3<\/sup><\/a>^,<\/sup>}^{4<\/sup><\/a>. These agents have also demonstrated additional metabolic benefits such as delayed gastric emptying and reduced appetite, which contribute to improved overall glycaemic outcomes and cardiometabolic health}^{7<\/sup><\/a>. While their main role remains in diabetes treatment, certain GLP-1 therapies are also approved for weight management in individuals with obesity or overweight with comorbidities, given their modest but clinically meaningful effects on appetite regulation and body weight}^{2<\/sup><\/a>^,<\/sup>}^{6<\/sup><\/a>^,<\/sup>}^{7<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
It is very important to keep in mind that GLP-1 drugs should not be used simultaneously with other GLP-1 containing products or combined with any other GLP-1 RA.\u00a0\u00a0<\/p>\n\n\n\n
Note:<\/strong> Please note that GLP-1 RAs are prescription medications and must be used only under the supervision of a qualified healthcare professional.\u00a0\u00a0<\/p>\n\n\n\n
<\/span>How Do GLP-1 RAs Work?<\/strong><\/span><\/h2>\n\n\n\n
$\"how$ <\/figure><\/div>\n\n\n
As mentioned above, a GLP-1 receptor agonist works by mimicking the natural incretin hormone (hormones secreted by the gut) GLP-1, which may assist in lowering blood sugar in the following ways ^{7<\/sup><\/a>^,<\/sup>}^{8<\/sup><\/a>:\u00a0<\/p>\n\n\n\n}
\n
Increase insulin when blood glucose (sugar) is high: <\/strong>They enhance the body\u2019s ability to release insulin when blood sugar levels are elevated. This could help bring glucose down in a controlled manner.\u00a0<\/li>\n\n\n\n
Decrease glucagon levels: <\/strong>They reduce the secretion of glucagon (a hormone that increases blood sugar). This may further help limit excessive glucose production by the liver.\u00a0<\/li>\n\n\n\n
Slow gastric emptying: <\/strong>They signal certain nerves to slow down the movement of food from the stomach into the intestine. This may help avoid rapid rises in blood glucose after meals.\u00a0<\/li>\n\n\n\n
Promote satiety: <\/strong>They act on appetite-regulating centres in the brain to increase the feeling of fullness after eating. This could, in turn, support reduced calorie intake.\u00a0<\/li>\n<\/ul>\n\n\n\n
Together, these steps support better glycaemic control and contribute to improved metabolic outcomes.\u00a0<\/p>\n\n\n\n
Note: <\/strong>These effects are observed and interpreted from clinical studies and should not be understood as direct personal guarantees for blood glucose or weight support.\u00a0<\/p>\n\n\n\n
<\/span>Common GLP-1 RA Medications<\/strong><\/span><\/h2><\/div>

Generic Name<\/strong>\u00a0<\/td>	Formulation <\/strong>\u00a0<\/td>	Approval <\/strong>\u00a0<\/td><\/tr>
Exenatide<\/strong><\/a><\/td>	Injectable\u00a0<\/td>	FDA and CDSCO approved\u00a0<\/td><\/tr>
Liraglutide<\/a><\/strong><\/td>	Injectable\u00a0<\/td>	FDA and CDSCO approved\u00a0<\/td><\/tr>
Dulaglutide<\/strong><\/a><\/td>	Injectable\u00a0<\/td>	FDA and CDSCO approved\u00a0<\/td><\/tr>
Semaglutide<\/strong><\/a>\u00a0<\/strong><\/td>	Both oral and injectable\u00a0<\/td>	FDA and CDSCO approved\u00a0<\/td><\/tr>
Lixisenatide<\/strong><\/a>\u00a0<\/strong><\/td>	Injectable\u00a0<\/td>	FDA and CDSCO approved\u00a0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Note:<\/strong> GLP-1 RAs differ in their dosing frequency (daily or weekly, depending on the agent). However, the specific type and dosage prescribed will depend on the clinical assessment made by the healthcare professional managing your treatment.\u00a0\u00a0<\/p>\n\n\n\n <\/span>When Are GLP-1 RA Prescribed?<\/strong><\/span><\/h2>\n\n\n\n GLP-1 drugs may be prescribed for the following conditions as per American Diabetes Association\/European Association for the Study of Diabetes (ADA\/EASD) 2025 guidelines^{11<\/sup><\/a>:\u00a0<\/p>\n\n\n\n} \n Primary glycaemic indication:<\/strong> GLP-1 RAs are recommended for adults with type 2 diabetes who have not reached their individualised A1C targets (typically when A1C is \u22651.5% above the agreed glycaemic goal) despite lifestyle measures and foundational therapy such as metformin.\u00a0<\/li>\n\n\n\n Cardiovascular benefit:<\/strong> In adults with type 2 diabetes who have established cardiovascular risk, a GLP-1 RA may provide cardiovascular benefit, independent of baseline A1C.\u00a0<\/li>\n\n\n\n Weight management\/metabolic effects:<\/strong> GLP-1 RAs may also support weight management in adults with type 2 diabetes who are overweight or obese, providing an added metabolic advantage alongside their primary glycaemic and cardioprotective effects.\u00a0<\/li>\n<\/ul>\n\n\n\n Note:<\/strong> These are guideline-based indications at a population level. Only a qualified healthcare professional can determine whether a GLP-1 RA is appropriate for an individual patient, based on a full clinical assessment.\u00a0<\/p>\n\n\n\n <\/span>Important Lab Tests for GLP-1 Users<\/strong><\/span><\/h2>\n\n\n\n People who are starting GLP-1 therapy or are already taking GLP-1 medications (such as semaglutide, liraglutide, dulaglutide) need regular health monitoring. These blood tests help ensure safety, effectiveness, and early detection of side effects.\u00a0<\/p>\n\n\n\n For convenience, PharmaEasy offers the following packages with comprehensive test panels for people starting or already using GLP-1 medications.\u00a0<\/p>\n\n\n\n 1. GLP-1 Health Checkup\/GLP-1 Advanced Monitoring (Includes 72 parameters)\u00a0<\/strong><\/h3>\n\n\n\n\n Pancreatic Tests:<\/strong> These help detect pancreatitis, a rare but important risk associated with GLP-1 medications^{12<\/sup><\/a>.\u00a0\n} \n Amylase Test<\/strong><\/a><\/li>\n\n\n\n Lipase Test\u00a0<\/strong><\/a><\/li>\n<\/ul>\n<\/li>\n\n\n\n Vitamin Tests:<\/strong> These are essential for detecting nutrient deficiencies, as GLP-1 medications may suppress appetite and reduce overall nutrient intake^{13<\/sup><\/a>.\u00a0\n} \n Vitamin B12 Test<\/strong>\u00a0<\/a><\/li>\n\n\n\n Vitamin D Total<\/strong><\/a>\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Lipid Profile Test<\/strong><\/a>:<\/strong> These assess cardiovascular risk and track improvements in cholesterol levels while on GLP-1 therapy^{14<\/sup><\/a>.\u00a0\n} \n Low-Density Lipoprotein (LDL) Cholesterol Direct Test<\/strong><\/a>\u00a0<\/li>\n\n\n\n Total Cholesterol (TC)<\/strong><\/a><\/li>\n\n\n\n High-Density Lipoprotein (HDL) Cholesterol Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Triglycerides (TRIG) Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Serum Very-Low-Density Lipoprotein (VLDL) Cholesterol\u00a0<\/li>\n\n\n\n LDL\/HDL Ratio\u00a0<\/li>\n\n\n\n TC\/HDL Cholesterol Ratio\u00a0<\/li>\n\n\n\n Non-HDL Cholesterol\u00a0<\/li>\n\n\n\n HDL\/LDL Cholesterol Ratio\u00a0<\/li>\n\n\n\n TRIG\/HDL Ratio\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Liver Function Tests (LFT)<\/strong><\/a>:<\/strong> These monitor liver health, especially important during rapid weight loss or fatty liver improvement^{14<\/sup><\/a>.\u00a0\n} \n Albumin Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Alkaline Phosphatase (ALP) Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Gamma Glutamyl Transferase (GGT) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Total Protein Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Serum Glutamate Pyruvate Transaminase (SGPT)\/Alanine Aminotransferase (ALT) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Aspartate Aminotransferase (AST)\/Serum Glutamate Oxaloacetate Transaminase (SGOT) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Bilirubin Direct<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Bilirubin Indirect\u00a0<\/li>\n\n\n\n Bilirubin Total\u00a0<\/strong><\/a><\/li>\n\n\n\n Albumin\/Globulin Ratio\u00a0<\/li>\n\n\n\n Globulin\u00a0<\/li>\n\n\n\n SGOT\/SGPT Ratio\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Thyroid Profile (T3, T4, TSH)<\/strong><\/a>: <\/strong>These <\/strong>ensure thyroid function remains stable, as hormonal balance may influence weight and metabolism^{15<\/sup><\/a>.\u00a0\n} \n Thyroxine (T4) Test<\/strong>\u00a0<\/a><\/li>\n\n\n\n Triiodothyronine (T3) Test<\/strong><\/a>\u00a0<\/li>\n\n\n\n Thyroid Stimulating Hormone \u2013 Ultrasensitive (UTSH)<\/strong><\/a>\u00a0<\/li>\n\n\n\n Electrolytes:<\/strong> These detect imbalances that may occur due to nausea and vomiting (possible side effects of GLP-1 medications)^{7<\/sup><\/a>^,<\/sup>}^{16<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Chloride (Cl) Test<\/strong><\/a>\u00a0<\/li>\n\n\n\n Potassium (K\u207a) Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Serum Sodium (Na) Test<\/strong><\/a>\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Renal\/Kidney Function (RFT\/KFT)<\/strong><\/a>:<\/strong> These monitor hydration and kidney health, as GLP-1 therapy might affect fluid balance^{17<\/sup><\/a>.\u00a0\n} \n Uric Acid Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Blood Urea Nitrogen (BUN) \/ Serum Urea<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Calcium (Ca) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Creatinine Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n eGFR<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n BUN\/Creatinine Ratio\u00a0<\/li>\n\n\n\n Urea\/Creatinine Ratio\u00a0<\/li>\n\n\n\n Urea (Calculated)\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Complete Blood Count and Haematology:<\/strong> These evaluate overall blood health, oxygen-carrying capacity, immunity, and inflammation^{18<\/sup><\/a>.\u00a0\n} \n Absolute Eosinophil Count (AEC) Test\u00a0<\/li>\n\n\n\n Haemoglobin (Hb) Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Platelet Count Test<\/strong><\/a>\u00a0<\/strong><\/li>\n\n\n\n Erythrocyte Count (RBC) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Mean Cell Volume (MCV) Test\u00a0<\/li>\n\n\n\n Mean Cell Haemoglobin (MCH) Test<\/strong><\/a>\u00a0<\/li>\n\n\n\n Mean Corpuscular Hb Concentration (MCHC)\u00a0<\/li>\n\n\n\n Total Leucocytes (TLC) \/White Blood Cell (WBC) Test\u00a0<\/strong><\/a><\/li>\n\n\n\n Absolute Lymphocyte Count (ALC) Test\u00a0<\/li>\n\n\n\n Absolute Basophils Count (ABC) Test\u00a0<\/li>\n\n\n\n Packed Cell Volume (PCV)\u00a0<\/li>\n\n\n\n Neutrophils\u00a0<\/li>\n\n\n\n Lymphocytes\u00a0<\/li>\n\n\n\n Monocytes\u00a0<\/li>\n\n\n\n Eosinophils\u00a0<\/li>\n\n\n\n Basophils\u00a0<\/li>\n\n\n\n Absolute Neutrophil Count\u00a0<\/li>\n\n\n\n Absolute Monocyte Count\u00a0<\/li>\n\n\n\n Immature Granulocyte Percentage\u00a0<\/li>\n\n\n\n Red Cell Distribution Width (RDW-SD)\u00a0<\/li>\n\n\n\n Nucleated Red Blood Cells Percentage\u00a0<\/li>\n\n\n\n Immature Granulocytes\u00a0<\/li>\n\n\n\n Nucleated Red Blood Cells\u00a0<\/li>\n\n\n\n Red Cell Distribution Width \u2013 Coefficient of Variation (RDW-CV)\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Cardiac Risk Markers:<\/strong> These assess inflammation and long-term cardiovascular risk, which may improve with GLP-1 therapies^{19<\/sup><\/a>.\u00a0\n} \n Apolipoprotein A1 (Apo A1)\u00a0<\/li>\n\n\n\n Apolipoprotein B (Apo B)\u00a0<\/li>\n\n\n\n High-Sensitivity C-Reactive Protein (hs-CRP)\u00a0<\/li>\n\n\n\n Lipoprotein (a)\u00a0<\/li>\n\n\n\n Apo B\/Apo A1 Ratio\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n Diabetes Monitoring Tests: <\/strong>These <\/strong>track blood sugar control and overall improvement in glycaemic health^{20<\/sup><\/a>.\u00a0\n} \n Haemoglobin A1C (HbA1c)<\/strong><\/a><\/li>\n\n\n\n Glycosylated Hemoglobin\u00a0<\/li>\n\n\n\n Average Blood Glucose\u00a0<\/li>\n\n\n\n Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Index Test\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n2. GLP-1 Monitoring with Vitals Package\/GLP-1 Package with Vitals (Includes all 72 tests above + 4 vital parameters)<\/strong><\/h3>\n\n\n\n\n Vitals:<\/strong> These track weight trends, BMI changes, and blood pressure improvements with GLP-1 therapy^{21<\/sup><\/a>.\u00a0\n} \n Blood Pressure Monitoring\u00a0<\/li>\n\n\n\n Height\u00a0<\/li>\n\n\n\n Weight\u00a0<\/li>\n\n\n\n Body Mass Index (BMI)\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n <\/span>Observed Effects and Awareness<\/strong><\/span><\/h2>\n\n\n\n Based on clinical research and reviews, GLP-1 receptor agonist:\u00a0<\/p>\n\n\n\n \n Help reduce A1C with improved glycaemic control in adults with type 2 diabetes ^{22<\/sup><\/a>^,<\/sup>}^{23<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} May assist in weight management in adults who are overweight or obese and have at least one weight-related condition (such as hypertension, type 2 diabetes, or high cholesterol)^{4<\/sup><\/a>^,<\/sup>}^{22<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} May provide additional metabolic benefits, including improved beta-cell function, reduced glucagon secretion, delayed gastric emptying, and increased satiety ^{22<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} May offer cardiovascular protection, with possible reductions in cases of major adverse cardiovascular events (MACE) such as myocardial infarction and stroke in high-risk populations ^{23<\/sup><\/a>.\u00a0<\/li>\n<\/ul>\n\n\n\nNote:<\/strong> <\/strong>It is important to understand that these agents (GLP-1 RAs) work best alongside healthy \u00a0 lifestyle measures and require regular monitoring. Further, while studies show several favourable effects, individual responses can still vary, and these outcomes are not guaranteed for every person.\u00a0\u00a0<\/p>\n\n\n\n} <\/span>GLP-1 RA Side Effects and Considerations<\/strong><\/span><\/h2>\n\n\n\nGLP-1 drugs are generally well-tolerated, but like all medications, they may also have specific side effects and important considerations that you should be aware of ^{7<\/sup><\/a>:\u00a0<\/p>\n\n\n\n} Side Effects<\/strong><\/h3>\n\n\n\n \n Gastrointestinal symptoms such as nausea, vomiting, and diarrhoea are the most common.\u00a0<\/li>\n\n\n\n Injection-site reactions (redness, itching) may occur with injectable formulations.\u00a0<\/li>\n\n\n\n Mild hypoglycaemia (low blood sugar) could occur, mainly when combined with other medications like insulin or sulfonylureas.\u00a0<\/li>\n\n\n\n Possible increased risk of gallbladder or biliary disorders, especially with long-term use.\u00a0<\/li>\n<\/ul>\n\n\n\n Clinical Considerations<\/strong><\/h3>\n\n\n\n \n Should be used cautiously in patients who have a history of pancreatitis.\u00a0<\/li>\n\n\n\n Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.\u00a0<\/li>\n\n\n\n May impact the absorption of oral medications and requires caution before procedures requiring fasting due to delayed gastric emptying effect.\u00a0<\/li>\n\n\n\n Patients with renal or hepatic impairment may require closer monitoring, especially if significant gastrointestinal symptoms lead to dehydration.\u00a0<\/li>\n<\/ul>\n\n\n\n Caution: <\/strong>If any side effects occur, <\/strong>always discuss with a doctor, as they can assess their severity, determine whether treatment adjustments are needed.\u00a0<\/p>\n\n\n\n <\/span>Lifestyle and Dietary Awareness<\/strong><\/span><\/h2>\n\n\n\n You can support your overall well-being by adopting healthy, supportive lifestyle measures, such as:\u00a0<\/p>\n\n\n\n \n Aiming for a healthy weight: <\/strong>Use tools like BMI and waist circumference to understand health risks. If BMI is over 30, aim for a goal between 18.5 to 24.9. Remember, even a 5 to 10% weight loss could improve metabolic outcomes^{24<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Choosing nutrient-dense foods: <\/strong>Focus on vegetables, fruits, lean proteins, whole grains, legumes, nuts, and healthy fats^{24<\/sup><\/a>^,<\/sup>}^{25<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Limiting refined\/processed foods: <\/strong>Reduce saturated fats, such as fast foods and refined vegetable oils^{24<\/sup><\/a>^,<\/sup>}^{25<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Staying hydrated:<\/strong> Replace sugar-sweetened beverages with water to reduce calorie load and avoid glucose spikes^{24<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Engaging in regular physical activity:<\/strong> Aim for at least 150 minutes of moderate exercise weekly plus strength training to improve metabolic function^{24<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Supporting good sleep habits:<\/strong> Aim for getting adequate sleep, as it helps reduce hunger signals and stress hormones that may interfere with metabolic health^{24<\/sup><\/a>.\u00a0<\/li>\n<\/ul>\n\n\n\n} <\/span>Natural Ways to Support GLP-1<\/strong><\/span><\/h2>\n\n\n\nIf you are wondering \u201chow to increase GLP-1 naturally,\u201d certain lifestyle habits, such as the following, may help support your body\u2019s own GLP-1 levels ^{26<\/sup><\/a>:\u00a0<\/p>\n\n\n\n} \n Choose high-fibre carbohydrates (like legumes, oats, barley, vegetables) since gut fermentation of fibre produces short-chain fatty acids that may stimulate GLP-1 release.\u00a0\u00a0<\/li>\n\n\n\n Include lean proteins in meals, which further enhance GLP-1 and support fullness.\u00a0\u00a0<\/li>\n\n\n\n Opt for healthy unsaturated fats (e.g., olive oil, avocado, fatty fish), which slow digestion and may enhance GLP-1 release.\u00a0\u00a0<\/li>\n\n\n\n While planning meals, use mindful portion sizes and consistent timing.\u00a0\u00a0<\/li>\n\n\n\n Support consistent physical activity, adequate sleep, and reduced stress, which together contribute to improved metabolic hormone responses, including GLP-1.\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n Note:<\/strong> These habits are for general metabolic support and are not a substitute for medical treatment or professional advice.\u00a0<\/p>\n\n\n\n <\/span>When to Consult a Doctor?<\/strong><\/span><\/h2>\n\n\n\n Monitoring your health while using a GLP-1 receptor agonist is important, and certain symptoms or situations, such as the ones below, should prompt a consultation with a doctor:\u00a0<\/p>\n\n\n\n \n New or worsening gastrointestinal symptoms, such as persistent nausea, vomiting, diarrhoea, or signs of dehydration ^{7<\/sup><\/a>^,<\/sup>}^{27<\/sup><\/a>.\u00a0<\/li>\n\n\n\n} Symptoms of low blood sugar, especially if taking insulin<\/a><\/strong> or sulfonylureas along with a GLP-1 RA ^{7<\/sup><\/a>.<\/li>\n\n\n\n} Severe abdominal pain ^{7<\/sup><\/a>.\u00a0<\/li>\n<\/ul>\n\n\n\n} You should also consult a doctor<\/a> in the following cases ^{7<\/sup><\/a>:\u00a0<\/p>\n\n\n\n} \n Before any planned surgery or procedure, as GLP-1 RAs may affect gastric emptying and fasting requirements.\u00a0<\/li>\n\n\n\n If pregnant, planning pregnancy, or breastfeeding, to review safety and treatment alternatives.\u00a0<\/li>\n\n\n\n Any unexpected or bothersome side effects, or if the medication does not seem to be working as expected.\u00a0<\/li>\n<\/ul>\n\n\n\n Regular follow-up is important. Additionally, you may always consult a doctor for guidance on dosing, side effects, or any concerns while using GLP-1 medications.\u00a0<\/p>\n\n\n\n *Also Read:* *Weight Loss Patches: What are They, How They Work, Effectiveness & Myths\u00a0<\/a><\/em><\/strong><\/p>\n\n\n\n* <\/span>Conclusion<\/strong><\/span><\/h2>\n\n\n\n GLP-1 receptor agonists represent an important therapeutic option for managing type 2 diabetes and, in certain cases, obesity. Their benefits, such as improved glycaemic control, support for weight management, and potential cardiovascular protection, are well documented in clinical studies. However, they must be used under the guidance of qualified healthcare professionals, as individual responses vary and careful monitoring is essential. Most importantly, alongside medication, healthy lifestyle habits and informed dietary choices play a key role in supporting long-term metabolic health.\u00a0<\/p>\n\n\n\n <\/span>Frequently Asked Questions (FAQs)<\/strong><\/span><\/h2>\n\n\n\nWhat is GLP-1 RA, and how does it work?<\/strong>\u00a0<\/strong> GLP-1 RAs are medications that work the same way as the natural GLP-1 hormone to help regulate blood sugar and support weight control. They work by increasing insulin when glucose is high, reducing glucagon, slowing stomach emptying, and promoting a feeling of fullness ^{7<\/sup><\/a>.<\/p> <\/div>} Which GLP-1 RAs are currently available?<\/strong>\u00a0<\/strong> Commonly available GLP-1 RAs include exenatide, liraglutide, dulaglutide, and semaglutide (injectable and oral)^{7<\/sup><\/a>. Please note that availability varies by country and regulatory approval.\u00a0<\/p> <\/div>} What are common side effects reported in studies?<\/strong>\u00a0<\/strong> The most frequently reported side effects are nausea, vomiting, diarrhoea, and mild hypoglycaemia (when used with certain other medications). Some individuals may also experience injection-site reactions or gallbladder-related symptoms ^{7<\/sup><\/a>.\u00a0<\/p> <\/div>} Can GLP-1 levels be influenced naturally?<\/strong>\u00a0<\/strong> Diet and lifestyle can modestly support natural GLP-1 activity. For example, high-fibre foods, balanced protein intake, regular exercise, adequate sleep, hydration, and limiting refined sugars may help enhance metabolic balance, though they do not replace medical treatment ^{23<\/sup><\/a>^,<\/sup>}^{24<\/sup><\/a>.\u00a0<\/p> <\/div>} Who should discuss GLP-1 RA with a doctor?<\/strong>\u00a0<\/strong> Anyone with type 2 diabetes needing better glucose control, individuals with obesity or weight-related health risks, or those with cardiovascular or kidney concerns should consult a doctor before using GLP-1 RAs. Medical guidance is also essential for people experiencing side effects or managing conditions such as pregnancy, pancreatitis, or thyroid-related risks ^{7<\/sup><\/a>.\u00a0<\/p> <\/div> <\/div>\n\n\n\n} <\/span>References<\/strong><\/span><\/h2>\n\n\n\n\n World Health Organization. Diabetes in India [Internet]. WHO; [cited 2025 Nov 17]. Available from: https:\/\/www.who.int\/india\/diabetes<\/a>\u00a0<\/li>\n\n\n\n Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A. Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2013 Jan;17(1):91-4. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3659913\/<\/a>\u00a0<\/li>\n\n\n\n Dharmalingam M. Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective. Ther Adv Endocrinol Metab. 2014 Dec;5(6):159-65. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4257981\/#bibr3-2042018814552657<\/a>\u00a0<\/li>\n\n\n\n Central Drugs Standard Control Organisation. List of new r-DNA origin drugs approved for import & marketing in India Jan 2020\u2013Jan 2025 [Internet]. CDSCO; [cited 2025 Nov 17]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadBiologicalrDNA\/CT-18A%20Approvals%20Jan,%202020%20%202025.pdf<\/a>\u00a0<\/li>\n\n\n\n U.S. Food and Drug Administration. FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes [Internet]. FDA; [cited 2025 Nov 17]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes<\/a>\u00a0<\/li>\n\n\n\n U.S. Food and Drug Administration. FDA approves new medication for chronic weight management [Internet]. FDA; [cited 2025 Nov 17]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management<\/a>\u00a0<\/li>\n\n\n\n Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. Treasure Island [Internet]. StatPearls Publishing; [cited 2025 Nov 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/<\/a>\u00a0<\/li>\n\n\n\n Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11304055\/<\/a>\u00a0<\/li>\n\n\n\n U.S. Food and Drug Administration. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity [Internet]. FDA; [cited 2025 Nov 17]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type<\/a>\u00a0<\/li>\n\n\n\n Central Drugs Standard Control Organisation. CDSCO Approved Drugs \/ Vaccines \/ r-DNA \/ Blood Product [Internet]. CDSCO; [cited 2025 Nov 17]. Available from: https:\/\/www.cdscoonline.gov.in\/CDSCO\/cdscoDrugs<\/a>\u00a0<\/li>\n\n\n\n American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S181-S206. Available from: https:\/\/diabetesjournals.org\/care\/article\/48\/Supplement_1\/S181\/157569\/9-Pharmacologic-Approaches-to-Glycemic-Treatment<\/a>\u00a0<\/li>\n\n\n\n Ayoub M, Chela H, Amin N, Hunter R, Anwar J, Tahan V, Daglilar E. Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. J Clin Med. 2025 Feb 1;14(3):944. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11818918\/<\/a>\u00a0<\/li>\n\n\n\n Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, Jones R. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr. 2025 Apr 25;12:1566498. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12062175\/<\/a>\u00a0<\/li>\n\n\n\n Chae Y, Kwon SH, Nam JH, Kang E, Im J, Kim HJ, Lee EK. Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2024 Aug;17(8):721-729. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38832475\/<\/a>\u00a0<\/li>\n\n\n\n Pirahanchi Y, Toro F, Jialal I. Physiology, thyroid stimulating hormone. StatPearls [Internet]. Treasure Island; [cited 2025 Nov 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499850\/<\/a>\u00a0<\/li>\n\n\n\n Open Resources for Nursing (Open RN). Chapter 15, Fluids and electrolytes. Nursing fundamentals [Internet]. Chippewa Valley Technical College; [cited 2025 Nov 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK591820\/<\/a>\u00a0<\/li>\n\n\n\n Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes. 2013 Oct 15;4(5):190-201. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3797884\/<\/a>\u00a0<\/li>\n\n\n\n Seo IH, Lee YJ. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review. Biomedicines. 2022 Oct 25;10(11):2697. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9687310\/<\/a>\u00a0<\/li>\n\n\n\n Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024 Sep 19;263(1):e240046. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11466209\/<\/a>\u00a0<\/li>\n\n\n\n Lee J, Kim MH, Jang JY, Oh CM. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin Diabetes Endocrinol. 2023 Nov 16;9(1):7. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10652621\/<\/a>\u00a0<\/li>\n\n\n\n Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, De Leon J. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025 Mar 13;15(3):408. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11940170\/<\/a>\u00a0<\/li>\n\n\n\n Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021 Mar 9;12:2042018821997320. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7953228\/<\/a>\u00a0<\/li>\n\n\n\n Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, et al. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review. Cureus. 2024 Sep 1;16(9):e68390. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11444311\/<\/a>\u00a0<\/li>\n\n\n\n Centers for Disease Control and Prevention. Healthy Weight: Keep it Off & Keep it Well [Internet]. CDC; [cited 2025 Nov 17]. Available from: https:\/\/www.cdc.gov\/diabetes\/living-with\/healthy-weight.html<\/a>\u00a0<\/li>\n\n\n\n Reynolds A, Mitri J. Dietary Advice For Individuals with Diabetes. Endotext [Internet]. NCBI; [cited 2025 Nov 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279012\/<\/a>\u00a0<\/li>\n\n\n\n Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Lifestyle Med. 2025 May 30:15598276251344827. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12125019\/<\/a>\u00a0<\/li>\n\n\n\n Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5397288\/<\/a>\u00a0<\/li>\n<\/ol>\n\n\n\n Disclaimer<\/em><\/strong>: The information provided here is for educational\/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.<\/em><\/p>\n\n\n\n Links and product recommendations in the information<\/em> provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products\/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.<\/em><\/p>\n<\/body><\/html>\n *\r\n* \r\n \r\n $\"Likes\"$ \r\n <\/a>\r\n 1 <\/span>\r\n<\/div> \r\n \r\n $\"Dislikes\"$ \r\n <\/a>\r\n <\/span>\r\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Introduction Diabetes continues to be a major public health concern in India. According to the World Health Organization (WHO), it is estimated that around 77 million adults are presently living with type 2 diabetes and nearly 25 million are classified as prediabetic. The situation is further alarming, with over half of these individuals remaining unaware [\u2026]","protected":false},"author":169,"featured_media":260287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[14037],"tags":[13953,13954],"acf":[],"_embedded":{"wp:featuredmedia":[{"source_url":"https:\/\/pharmeasy.in\/blog\/wp-content\/uploads\/2025\/12\/glp-1-receptor-agonist.webp"}]},"_links":{"self":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/260270"}],"collection":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/users\/169"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/comments?post=260270"}],"version-history":[{"count":45,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/260270\/revisions"}],"predecessor-version":[{"id":275662,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/260270\/revisions\/275662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media\/260287"}],"wp:attachment":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media?parent=260270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/categories?post=260270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/tags?post=260270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}